memo - Magazine of European Medical Oncology

Herausgeber

Springer Wien

International Standard Serial Number (ISSN )

1865-5041

Electronic International Standard Serial Number ( EISSN )

1865-5076

ISSN gedruckt

1865-5041

URL

http://www.bibliothek.uni-regensburg.de/ezeit/?2428960

Weitere Details

2024

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives.

2023

Direct Effects of Ponatinib on Vascular Endothelial Cells: a Potential Explanation for Development of Vascular Adverse Events in Patients with CML.

2017

Effects of ponatinib on endothelial cells may explain the occurrence of vascular adverse events in ponatinib-treated patients with CML.

2016

Characterization of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem- and progenitor cells in patients with AML and CML.

2015

An update of functional data regarding the pro-atherogenic and anti-angiogenic effects of nilotinib in patients with Ph+ CML.

2014

Nilotinib induces Pro-Atherogenic and Anti-Angiogenic Effects on Human Vascular Endothelial Cells: A Potential Explanation for Drug-induced Vasculopathies in CML Patients.

2013

The Austrian Competence Network on Mastocytosis (AUCNM): A partner and part of the European ECNM network.

2009

The H1 Receptor Antagonists Terfendine and Loratadine inhibit Growth and induce Apoptosis in Neoplastic Mast Cells.

2008

Antiproliferative Effects of KIT Tyrosine Kinase Inhibitors in Feline Neoplastic Mast Cells.

Download
RDF/XML-Format
JSON-LD-Format
Turtle-Format
N3-Format

2024

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives.

2023

Direct Effects of Ponatinib on Vascular Endothelial Cells: a Potential Explanation for Development of Vascular Adverse Events in Patients with CML.

2017

Effects of ponatinib on endothelial cells may explain the occurrence of vascular adverse events in ponatinib-treated patients with CML.

2016

Characterization of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem- and progenitor cells in patients with AML and CML.

2015

An update of functional data regarding the pro-atherogenic and anti-angiogenic effects of nilotinib in patients with Ph+ CML.

2014

Nilotinib induces Pro-Atherogenic and Anti-Angiogenic Effects on Human Vascular Endothelial Cells: A Potential Explanation for Drug-induced Vasculopathies in CML Patients.

2013

The Austrian Competence Network on Mastocytosis (AUCNM): A partner and part of the European ECNM network.

2009

The H1 Receptor Antagonists Terfendine and Loratadine inhibit Growth and induce Apoptosis in Neoplastic Mast Cells.

2008

Antiproliferative Effects of KIT Tyrosine Kinase Inhibitors in Feline Neoplastic Mast Cells.

Download
RDF/XML-Format
JSON-LD-Format
Turtle-Format
N3-Format